



03Cw

0420  
03/20/02Attorney/Docket No. 28758.57  
Customer No. 000027683

24

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Pollak, et. al.

Serial No: 10/025,350

Filed: December 18, 2001

For: CIRCULATING INSULIN-LIKE  
GROWTH FACTOR-I AND  
PROSTATE CANCER RISK§  
§  
§  
§  
§  
§  
§  
§  
§  
§

Group Art Unit: Unknown

Examiner: Unknown

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**Commissioner For Patents  
Washington, D.C. 20231


Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and are not in any order based on their pertinence. Copies of the listed information are attached.

This Information Disclosure Statement is being filed within three months of the United States filing date or before the mailing date of a first Office Action on the merits. No certification or fee is required (37 CFR 1.97(b)).

It is requested that the Examiner fully consider the cited references and that they be cited on the front of any patent issuing from this application. An early action on the merits is respectfully requested. The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account 08-1394.

Respectfully submitted,

  
Brian J. Hubbard  
Reg. No. 45,873Date: March 14, 2002  
HAYNES AND BOONE, LLP  
901 Main Street, Suite 3100  
Dallas, Texas 75202-3789  
Telephone: 214-651-5058  
Facsimile: 214-651-5940  
D-1000219.1

<p align="center"><b>Certificate of Mailing</b></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner For Patents, Washington, D.C. 20231 on <u>March 15, 2002</u></p> <p><u>SANDRA KUBIN</u></p> <p>Printed Name</p> <p><u>Sandra Kubin</u></p> <p>Signature</p>
--




In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/025,350
				Filing Date	December 18, 2001
				Applicant(s)	Pollak, et al.
				Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	28758.57
SHEET	1	OF	2		

U. S. PATENT DOCUMENTS				
Examiner's Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	5,614,372	March 25, 1997	Lilja, et al.

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N
	B1	WO 96 26442	August 29, 1996	Lilja, et al.	

OTHER PRIOR ART		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume-issue number(s), publisher, city/country where published
	C1 \	Baserga, Renato, "The Insulin-like Growth Factor I Receptor: A key to Tumor Growth?" Cancer Research (1995) 55:249-252.
	C2 \	Carter, et al., "The Prostate: An Increasing Medical Problem", Prostate (1990) 16: 39-48.
	C3 \	Catalona et al., "Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination: Enhancement of Specificity With Free PSA Measurements", JAMA (1997) 277 (18): 1452-1455.
	C4 \	Cats et al., "Increased Epithelial Cell Proliferation in the Colon of Patients with Acromegaly", Cancer Research (1996) 56: 523-526.
	C5	Chen, et al., "Prostate Specific Antigen in Benign Prostatic Hyperplasia: Purification and Characterization", J. of Urology (1997) 157: 2166-2170.
	C6 \	Cho, et al., "Expression of Alpha-1 antichymotrypsin in Prostate Carcinoma", J Korean Med Sci. (1997) 12(3): 228-233 1997.
	C7	Cohen et al., "Physiologic and clinical relevance of the insulin-like growth factor binding proteins", Current Opinion in Pediatrics, (1994) 6:462-467.
	C8 \	Giudice, Linda C., "Editorial: IGF Binding Protein-3 Protease Regulation: How Sweet It Is!", J. of Clinical Endocrinology & Metabolism (June 15, 1997) 80(8): 2279-2281.
	C9 \	Glick et al., "Insulin-Like growth factors in central nervous system tumors", J. Neuro-Oncology (1997) 35: 315-325
	C10	Hankinson et al., "Circulating concentrations of insulin-like growth factor-I and risk of breast cancer", Lancet (1998) 351(9113): 1373-1374.
	C11 \	Harrela et al., "Genetic and Environmental Components of Interindividual Variation in Circulating levels of IGF-1, IGF-II, IGFBP-1, and IGFBP-3", J. Clin. Invest. (1996) 98(11): 2612-2615.
	C12	Juul et al., "The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF Binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients", Clinical Endocrinology (1994) 41: 85-93.
	C13	Kao et al., "Insulin-Like Growth Factor-I Comparisons in Healthy Twin Children", J. Clinical Endocrinology & Metabolism (1994) 78(2):310-312.
	C14	Kelley et al., "Insulin-like Growth Factor-binding Proteins (IGFBPs) and Their Regulatory Dynamics", Int. J. Biochem. Cell Biol. (1996) 28:619-637.



	C15	Khosravi <i>et al.</i> , "Noncompetitive ELISA for human serum insulin-like growth factor-I", Clinical Chemistry (1996) 42(8): 1147-1154.
	C16	Khosravi, <i>et al.</i> , Immunoassay of insulin-like growth factor binding protein-I", Clinical Chemistry (1997) 43(3): 523-532.
	C17	Lahm <i>et al.</i> , "Blockade of the Insulin-Like Growth-Factor-I Receptor Inhibits Growth of Human Colorectal Cancer Cells: Evidence of a Functional IGF-II-Mediated Autocrine Loop", Int. J. Cancer (1994) 58: 452-459.
	C18 ✓	Lamson <i>et al.</i> "Insulin-Like Growth Factor Binding Proteins: Structural and Molecular Relationships", Growth Factors (1991) 5:19-28.
	C19 ✓	Lee <i>et al.</i> , "Active Insulin-Like Growth Factor-I (IGF-I) Assays", Technical Release, Diagnostic Systems Laboratories, Inc. pp 1-8.
	C20	Li <i>et al.</i> , "Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder and paraganglioma tumors", Cell Tissue Res (1998) 291: 469-479.
	C21	Luderer <i>et al.</i> , "Measurement of the proportion of Free to Total Prostate-Specific Antigen Improves Diagnostic Performance of Prostate-Specific Antigen in the Diagnostic Gray Zone of Total Prostate-Specific Antigen", Urology (1995) 46(2): 187-194.
	C22 ✓	Oh, Youngman, "IGF-independent regulation of breast cancer growth by IGF binding proteins", Breast Cancer Research and Treatment (1998) 47: 283-293.
	C23 ✓	Orme <i>et al.</i> , "Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study", J. Clinical Endocrinology & Metabolism (1998) 83(8): 2730-2734.
	C24	Rajah <i>et al.</i> " Insulin-Like Growth Factor Binding Protein (IGFBP) Proteases: Functional Regulators of Cell Growth", Progress in Growth Factor Research (1995) 6(2-4):273-284.
	C25	Rajaram <i>et al.</i> "Insulin-Like Growth Factor Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions" Endocrine Reviews (1997) 18(6): 801-831.
	C26 ✓	Russell <i>et al.</i> , "Growth factor involvement in progression of prostate cancer, " Clinical Chemistry (1998) 44(4): 705-723.
	C27 ✓	Stenman <i>et al.</i> , " A Complex Between Prostate-specific Antigen and $\alpha$ 1-Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer", Cancer Research (1991) 51: 222-226.
	C28 ✓	Valentinis <i>et al.</i> , "The Human Insulin-Like Growth Factor (IGF) Binding Protein-3 Inhibits the Growth of Fibroblasts with a Targeted Disruption of the IGF-I Receptor Gene" Molecular Endocrinology (1995) 9: 361-367.
	C29	Woodrum <i>et al.</i> , "Analysical performance of the Tandem®-R free immunoassay measuring free prostate-specific antigen" Clinical Chemistry (1997) 43(7): 1203-1208.
	C30 ✓	Yu <i>et al.</i> , "Insulin-Like Growth Factor-Binding Protein-3 and Breast Cancer Survival" Int. J. Cancer (Pred. Oncol.) (1998) 79: 624-628.
	C31	Zadeh <i>et al.</i> , " The 16-kDa Proteolytic Fragment of Insulin-like Growth Factor (IGF) Binding Protein-3 Inhibits the Mitogenic Action of Fibroblast Growth Factor on Mouse Fibroblasts with a Targeted Disruption of the type 1 IFG Receptor Gene" Endocrinology (1997) 138(7): 3069-3072.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.